RxDoctor Payments DataLook up a doctor →

Keith Woo, MD

Internal Medicine · Honolulu, HINPI 1366595092

Payments from drug & device makers

$105,855in general payments, 2019–2025

Across 649 payments — averaging $163.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$46K
  • Amarin Pharma, Inc.$43K
  • Amgen$2K
  • Gilead$2K
  • Bayer$2K
  • AstraZeneca$1K
  • plus $9K from 32 others

What the payments were for

  • Speaking & faculty fees$72,24068%
  • Travel & lodging$11,29911%
  • Food & beverage$22,21121%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,855 in reported general payments places this provider in the 95th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$20,668
Medicare patients
34
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl502$413,231
CreonLipase/Protease/Amylase197$407,740
FarxigaDapagliflozin Propanediol248$299,164
LinzessLinaclotide165$177,842
JardianceEmpagliflozin110$163,891
EliquisApixaban67$87,656
KerendiaFinerenone53$74,240
JanuviaSitagliptin Phosphate51$54,515
RybelsusSemaglutide20$41,560
LivaloPitavastatin Calcium40$34,182
OzempicSemaglutide22$31,594
Janumet XrSitagliptin Phos/Metformin Hcl27$31,549
XareltoRivaroxaban25$31,001
VemlidyTenofovir Alafenamide18$28,173
Diclofenac Epolamine27$22,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$46,352$585,582362 claims
AstraZenecaFarxiga$1,413$299,164248 claims
Boehringer IngelheimJardiance, Synjardy$595$185,159130 claims
PfizerEliquis$720$87,65667 claims
MerckJanuvia, Janumet Xr$95$86,06378 claims
BayerKerendia$1,787$74,24053 claims
Novo NordiskRybelsus, Ozempic$1,149$73,15442 claims
Kowa Pharmaceuticals America, Inc.Livalo$325$34,18240 claims
Johnson & JohnsonXarelto$746$31,00125 claims
GileadVemlidy$2,033$28,17318 claims
Otsuka America Pharmaceutical, Inc.Rexulti$398$16,48513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →